Bladder and Renal
The following list provides a brief description of bladder and renal cancer trials that are recruiting participants in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.
Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.
Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.
#UpFrontPSMA
| Registered Title | #UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer |
| Purpose | This phase 2 randomised clinical trial will compare the effectiveness of Lu-PSMA therapy followed by docetaxel chemotherapy versus docetaxel chemotherapy on its own in patients with newly-diagnosed high-volume metastatic hormone-naive prostate cancer (mHNPC). |
| Lay Summary | N/A |
| WA Trial Sites |  (oncology) Ph. 08 615 26530 |
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
ENZA-p (ANZUP1901)
| Registered Title | ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide |
| Purpose | This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy. |
| Lay Summary | N/A |
| WA Trial Sites | (oncology) Ph. 08 615 26530 |
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
CheckMate 901
| Registered Title | A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer |
| Purpose | The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating patients with previously untreated inoperable or metastatic urothelial cancer. |
| Lay Summary | N/A |
| WA Trial Sites |  Ph. (08) 9242 7640 |
| Links | US National Library of Medicine |
BCG+MM (ANZUP1301)
| Registered Title | Adding Mitomycin to Bacillus of Calmette-Guerin (BCG) as Adjuvant Intravesical Therapy for High-risk, Non-Muscle-invasive Bladder Cancer: a Randomised Phase 3 Trial |
| Purpose | Open label, randomised phase 3 trial of the addition of Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer. The study aim is to compare disease-free survival between treatment arms: BCG alone versus Mitomyicn in addition to BCG. |
| Lay Summary | N/A |
| WA Trial Sites | Urology |
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
APOLLO
| Registered Title | A Phase 1/2 Dose Escalation and Expansion Study of Combination APL-501 or Nivolumab With APL-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma |
| Purpose |
This is an open-label Phase 1/2 study to assess the safety and tolerability of combination |
| Lay Summary | N/A |
| WA Trial Sites |
|
| Links | US National Library of Medicine |
NINJA
| Registered Title | The NINJA Clinical Trial: Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation (TROG 18.01 NINJA) |
| Purpose | "The NINJA clinical trial aims to compare two emerging schedules of radiotherapy in the treatment of prostate cancer. |
| Lay Summary | N/A |
| WA Trial Sites |  Ph. (08) 6383 3204 |
| Links | Australian New Zealand Clinical Trial Registry |
Acknowledgments: Australian New Zealand Clinical Trial Registry
NIAGARA / D933RC00001
| Registered Title | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer. |
| Purpose | A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer |
| Lay Summary | N/A |
| WA Trial Sites | Cancer Centre Clinical Trials Unit Ph. 08 615 26530 |
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
CA224-020
| Registered Title | A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors |
| Purpose | The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. |
| Lay Summary | N/A |
| WA Trial Sites |  Linear Clinical Research Ph. 08 6382 5513 |
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
BGB-900-103
| Registered Title | A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors |
| Purpose | This is an open-label, multicenter, non-randomized Phase 1b clinical trial for patients with histologically or cytologically confirmed locally advanced or metastatic tumors including non-squamous or squamous NSCLC, RCC, OC, or melanoma. |
| Lay Summary | N/A |
| WA Trial Sites |
|
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
PCR-MIB (ANZUP1502)
| Registered Title | Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer |
| Purpose | This study will enrol patients with maximally resected (via transurethral resection (TURBT) non-metastatic muscle invasive bladder cancer, who either wish to attempt bladder preservation therapy or are ineligible for cystectomy |
| Lay Summary | N/A |
| WA Trial Sites | SCGH Medical Oncology Ph. (08) 6383 3000 |
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
KEYPAD (ANZUP1601)
| Registered Title | Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma: a Phase II Trial (ANZUP 1601) |
| Purpose | This Single-arm, multicentre, phase 2 trial aims determine the activity and safety of pembrolizumab and denosumab in advanced clear cell renal cell carcinoma (ccRCC). |
| Lay Summary | N/A |
| WA Trial Sites |
|
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
NILE
| Registered Title | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer |
| Purpose | This is a study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra). |
| Lay Summary | N/A |
| WA Trial Sites | FSH (oncology) Cancer Centre Clinical Trials Unit Ph. 08 615 26530 |
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
CA017-078
| Registered Title | A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer |
| Purpose | A study to evaluate nivolumab + chemotherapy or nivolumab/ BMS-986205 + chemotherapy followed by continued Immuno-Oncology therapy after radical cystectomy (RC) compared with neoadjuvant standard of care (SOC) chemotherapy alone in patients with muscle-invasive bladder cancer (MIBC) |
| Lay Summary | N/A |
| WA Trial Sites |  Murdoch Oncology Clinical Trials UnitPh. (08) 9428 8539 |
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
CA045-009
| Registered Title | A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible |
| Purpose | The purpose of the study is to see if treatment with nivolumab plus NKTR-214 or nivolumab alone, before and after surgery to remove the bladder, is more effective than surgery alone in participants with muscle-invasive bladder cancer who are not able to receive cisplatin chemotherapy. |
| Lay Summary | N/A |
| WA Trial Sites | Murdoch Oncology Clinical Trials Unit Ph. (08) 9428 8539 |
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
THOR (ST-617)
| Registered Title | A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations |
| Purpose | The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-PD-(L) 1 agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2). |
| Lay Summary | N/A |
| WA Trial Sites |
|
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
